A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...

After Generation Bio telegraphed plans to lay off 90% of its staff this summer, Xoma Royalty has come knocking to bring yet ...

The FDA has cleared an augmented reality platform for real-time use during brain surgery—which its developer, Medivis, ...

MapLight Therapeutics is the latest biotech to want a turn with Alphabet’s AI spinout SandboxAQ. | MapLight Therapeutics is ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

The biotech’s lead asset, AVD-104, failed to beat Astellas’ Izervay at slowing the rate of retina lesion growth, the primary ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

Less than six months after a series A fundraise, AI drug developer Chai Discovery has brewed up a $130 million series B to ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Lumexa Imaging hauled in $462.5 million during its initial public offering, far exceeding the $200 million the outpatient ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...